The first FDA approved product from INOVIO’s DNA medicine platform
Harnessing the Power of In Vivo Protein Production
INOVIO is a biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. We use proprietary technology to design DNA plasmids — small circular DNA molecules that work like software that the body’s cells can download to learn how to produce specific proteins to target and fight disease.
LEARN MORE ABOUT OUR TECHNOLOGY →Where unmet need meets innovation.
We’re leveraging a cutting-edge platform to change treatment paradigms and improve lives.
LEARN MORE ABOUT OUR PIPELINE →The approval of VOCERYQ is a landmark achievement as we work to bring DNA medicines to the patients who need them most.”
Latest News
-
INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
READ MORE → -
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
READ MORE → -
INOVIO to Participate in Upcoming Investor Conferences
READ MORE →